ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.
|Articles|March 11, 2013
Privatizing the Medicaid expansion: 'Every State Will be Eying This'
Advertisement
Arkansas has turned heads with its plan to expand Medicaid using the private insurance market. The idea — which is still preliminary — would be to use Medicaid dollars to buy private insurance coverage for the expansion population.
For health policy experts, this has raised a huge number of questions: Will private plans guarantee the same benefits that Medicaid does? How will states pay for the private insurance, which generally costs more than the public program? And does HHS even have the legal authority to do this?
Read the full story:
Source: The Washington Post
Advertisement
Related to this article
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.
Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.
Activated memory B cells were already enriched at treatment end in the 5 of 21 patients who later cleared HBsAg
Specialty pharmacy leaders will gather in National Harbor for inSPire2026, tackling cell and gene therapy access, AI, and high-cost drug pricing.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
A 20-year Danish registry study found higher antidepressant and anxiolytic use among women with endometriosis, both before and after diagnosis.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
3
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
4
Which Antibiotics Raise C. Diff Risk Most? Jason Pogue, PharmD
5